No evidence Ozempic and Wegovy raise risk of self harm, EU regulators said

The European Medicines Company regulatory committee introduced the outcomes of its assessment on Friday. It’s the newest group to conclude there’s no recognized tie between a brand new class of weight problems medicine and suicide.

In January, the U.S. Meals and Drug Administration stated a preliminary assessment confirmed no proof of such a hyperlink, although the company stated it couldn’t rule out that “a small danger might exist” and that it will proceed to check the difficulty. A federally funded U.S. examine additionally discovered that folks taking semaglutide, the remedy in Ozempic and Wegovy, had a decrease danger of suicidal ideas than these taking older drugs to deal with diabetes and weight problems.

The assessment by the European Union’s regulators was triggered final July by anecdotal studies that folks taking the medicine had ideas of self-harm. The regulators examined research, post-marketing knowledge and different analysis associated to drugs utilized in practically a dozen medicine used to deal with the ailments. The group didn’t assessment data relating to tirzepatide, the remedy utilized in medicine bought as Mounjaro and Zepbound.

Each companies stated they’d proceed to carefully monitor studies of suicidal ideas or actions in individuals taking the medicine referred to as GLP-1 receptor agonists. Sufferers taking the medicine ought to report any psychological well being or different issues to their well being care suppliers, officers stated.